Neoadjuvant Crizotinib for ALK Re-arranged NSCLC?

J Thorac Oncol. 2019 Apr;14(4):574-576. doi: 10.1016/j.jtho.2019.01.004.

Authors

Tamas F Molnar¹, Annamaria Szipocs², Zsuzsanna Szalai²

Affiliations

¹ Department of Operational Medicine, Medical Faculty, University of Pécs, Pécs, Hungary; St. Sebastian Thoracic Surgery Unit, Department of Surgery, Aladar Petz University Teaching Hospital, Győr, Hungary. Electronic address: tfmolnar@gmail.com.
² Department of Pulmonology, Aladar Petz University Teaching Hospital, Győr, Hungary.

PMID: 30922571
DOI: 10.1016/j.jtho.2019.01.004

No abstract available

Publication types

Editorial
Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung*
Crizotinib
Humans
Lung Neoplasms*
Neoadjuvant Therapy
Protein Kinase Inhibitors
Receptor Protein-Tyrosine Kinases

Substances

Protein Kinase Inhibitors
Crizotinib
Receptor Protein-Tyrosine Kinases